|
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
LEF1 is a sensitive and specific marker for CLL and is helpful in the diagnosis of diagnostically challenging small B-cell lymphomas.
|
28395058 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
These data support the notion that CLL can differentiate into ISC and that this triggers decreased leukemic cell survival secondary to the down regulation of LEF-1 and decreased Wnt pathway activation.
|
21998751 |
2011 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Moreover, we identified lymphoid enhancer-binding factor 1 (LEF1), a downstream effector of the Wnt/β-catenin pathway, as a transcription repressor of CYLD in CLL.
|
22157808 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Additionally, due to aberrant LEF1 activity resulting in cancer progression, knockdown and inhibition treatments designed to target LEF1 have proven effective in alleviating cancer growth, migration, and invasion in CLL, CRC, glioblastoma multiforme (GBM), and renal cell carcinoma (RCC).
|
28670499 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
This study has identified the constitutive activation and prosurvival function of LEF-1 and the Wnt pathway in CLL and uncovered a possible role for these factors in the preleukemic state of monoclonal B-cell lymphocytosis.
|
20595513 |
2010 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
However, acute myeloid leukemia and acute lymphocytic leukemia showed a significantly increased fraction of the oncogenic LEF-1 compared with chronic lymphocytic leukemia and chronic myeloid leukemia.
|
15756419 |
2005 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
This study demonstrates that although LEF-1 mRNA is universally, highly expressed in B-CLL, expression of this gene is much lower or absent in the majority of low-grade B-cell non-Hodgkin's lymphoma (NHL).
|
16054689 |
2006 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In CLL, cortactin positivity did correlate with LEF1 and CD200 expression, and the combined positivity for ≥2 markers strongly predicted CLL diagnosis.
|
30458196 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In contrast, chronic lymphocytic leukemia (CLL) cells show constitutionally active Wnt signaling, which is associated with upregulated levels of pathway members such as Wnt3 and lymphoid enhancer-binding factor-1.
|
24793644 |
2014 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
A set of four genes was able to discriminate clonal BL from WM and CLL: LEF1 (WNT/beta-catenin pathway), MARCKS, ATXN1 and FMOD.
|
17252022 |
2007 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The results of this study indicate that methylprednisolone can suppress Wnt signaling pathway by down-regulating LEF-1 protein expression, indicating a novel mechanism for HDMP therapy in CLL.
|
26339357 |
2015 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Our results showed, for the first time, that high LEF1 expression is associated with poor survival for CLL patients.
|
26950276 |
2016 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bioinformatic analyses were utilized to define the expression of MYC-regulated genes in human colon cancer and metabolomics analyses were used to identify pathways regulated by LEF1 in MYC expressing cells.
|
31623618 |
2019 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Nr-CAM and LEF-1 expression was elevated in human colon cancer tissue and cell lines and in human malignant melanoma cell lines but not in melanocytes or normal colon tissue.
|
12183361 |
2002 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We report here that LEF1 is a new type of target gene ectopically activated in colon cancer.
|
11326276 |
2001 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A deeper understanding of these processes might improve the targeted therapies for colon cancer by regulating the expression of LEF-1.
|
22639890 |
2012 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We demonstrate that miR26b expression is a potent inhibitor of colon cancer cell proliferation and significantly decreases LEF1 expression.
|
24785257 |
2014 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A total of 106 colon cancer and matched paratumorous normal tissues were used to assess LEF1 expression using immunohistochemistry and qRT-PCR.
|
24098538 |
2013 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our findings identify LEF-1 as key regulator of beta-catenin nuclear localization and stability and suggest that overexpression of LEF-1 in colon cancer and melanoma cells may contribute to the accumulation of oncogenic beta-catenin in the nucleus.
|
11986304 |
2002 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Recent implications for beta-catenin signaling in cancer prompted us to examine colon cancer cell lines for the expression of LEF-1, a transcription factor that binds to beta-catenin.
|
9419974 |
1997 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here we characterize the biological activity of a hairpin polyamide 1 that inhibits binding of the minor-groove transcription factor LEF-1, constitutively expressed in colon cancers.
|
12144926 |
2002 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
The LEF1 gene is aberrantly transcribed in colon cancers because promoter 1 (P1) is a Wnt target gene and is activated by TCF-β-catenin complexes.
|
20525792 |
2010 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here we show that the regulation of the expression of this enzyme in a colon cancer cell line, and in patients, is associated with overexpression of the Wnt pathway-associated proteins, Pontin52/TIP49a and LEF-1.
|
14675489 |
2003 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conclude that the biological outcome of aberrant LEF1 activation in colon cancer is directed by differential promoter activation and repression.
|
16809766 |
2006 |
|
Malignant tumor of colon
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recently, alterations of LEF-1 isoforms distribution have been described in colon cancer.
|
15756419 |
2005 |